Eli Lilly (LLY) Stock Rises 7% Year-to-Date with Major Catalysts Ahead

Eli Lilly (NYSE: LLY) has increased 7% since January 2026, underperformed compared to the broader market. In Q1 2026, sales surged 56% year-over-year, largely from its GLP-1 drug sales, with Mounjaro up 125% and Zepbound up 80%. The company is preparing to submit a Biologics License Application for retatrutide, its next product, to the FDA early next year, targeting a 2027 launch. Eli Lilly's upcoming earnings release on August 5 may affect stock performance, especially since it currently has a high P/E ratio of 34 times earnings, indicating a potential price adjustment. This information matters for investors evaluating potential entry points in LLY stock.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.